Pimecrolimus topical

Drug Profile

Pimecrolimus topical

Alternative Names: ASM 981; Douglan; Elidel; Pimecrolimus cream; SDZ ASM 981; Topical pimecrolimus - Novartis

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antipsoriatics; Macrolides
  • Mechanism of Action Calcineurin inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis
  • No development reported Dry eyes; Seborrhoeic dermatitis; Vitiligo
  • Discontinued Psoriasis

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 17 Apr 2016 Biomarkers information updated
  • 01 Jul 2015 LEO Pharma completes a phase I trial for Atopic dermatitis in Canada and Israel (Topical) (NCT02376049)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top